Reyvow (lasmiditan) / Ildong, Eli Lilly, Daiichi Sankyo, Organon - LARVOL DELTA

New trends in migraine management: Transcending the traditional divide between acute and preventive treatments (EHF-EHC 2025) - "Acute medications like lasmiditan and rimegepant not only relieve symptoms quickly but also lower attack frequency and disease impact over time. Clinicians should understand that acute and preventive treatments are linked goals to improve management and prevent progression. Personalized plans are needed to enhance both treatments and lessen the overall impact on patients."

CNS Disorders • Migraine • Pain

Lasmiditan-overuse headache?: Time-series clustering analysis for treatment pattern of lasmiditan for two years from the initial prescription (EHF-EHC 2025) - "There might be a possibility of lasmiditan overuse. The appropriate use of lasmiditan should continue to be investigated."

Cardiovascular • CNS Disorders • Migraine • Pain

Investigation of the relationship between weather and headache attacks: Smartphone application data analyzed with artificial intelligence (EHF-EHC 2025) - "Using data from January to December 2023, we selected users who had used triptans or lasmiditan at least once and recorded headaches on 1–14 days per month, identifying them as having episodic migraine...Barometric pressure patterns classified as Type I (persistently low), Type II (dropping around the headache), and Type IV (persistently high) were also linked to more frequent headache reports. This real-world big data analysis demonstrated that several weather conditions—including rain, sunshine, wind, and falling barometric pressure—are significantly related to hourly headache occurrence."

CNS Disorders • Migraine • Pain

Loss of HTR1F Expression Increases Mortality and Prevents Lasmiditan-Induced Kidney Recovery After Moderate to Severe AKI in Mice (KIDNEY WEEK 2025) - "Both WT-Purchased and HTR1F Fl/Fl Las-treated mice exhibited a ~20% reduction in SCr 7d post I/R-AKI compared to vehicle-treated controls, an effect not observed in EIIa-Cre/HTR1F Fl/Fl mice. Conclusion These data underscore the importance of HTR1F expression and agonism in renal repair and recovery, and further highlight the repurposing potential of lasmiditan for the treatment of AKI and/or KD onset/progression."

Preclinical • Acute Kidney Injury • Cardiovascular • Fibrosis • Immunology • Metabolic Disorders • Nephrology • Renal Disease • Reperfusion Injury

Lasmiditan ameliorates cortico-hippocampal pathology and improves cognition in aging parkinsonian mice. (PubMed, Exp Neurol) - "In older (10-11.5 months old) mice, although the effects were milder, daily lasmiditan administration increased MB and bettered cognitive abilities. In essence, these findings indicate that repurposing lasmiditan could be a potential strategy to address PD-related cognitive decline."

Journal • Preclinical • CNS Disorders • Cognitive Disorders • Metabolic Disorders • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • THY1

Time-series clustering analysis for treatment pattern of lasmiditan for 2 years from the initial prescription. (PubMed, Ther Adv Neurol Disord) - "The identification of three distinct trajectories highlights the heterogeneity of clinical practice. It underscores the need for further research on lasmiditan's optimal use, particularly regarding combination therapy and potential medication overuse."

Journal • Cardiovascular • CNS Disorders • Migraine • Pain

5-hydroxytryptamine 1F receptor loss reduces renal vasculature and prevents lasmiditan-induced recovery following moderate-severe acute kidney injury in mice. (PubMed, Am J Physiol Renal Physiol) - "Furthermore, mice lacking the HTR1F exhibit decreased innate renal cortical vasculature, exacerbated rarefaction, and markedly increased mortality rates following moderate-severe I/R-AKI. These findings not only underscore the importance of HTR1F expression and agonism in renal repair and recovery, but also further highlight the repurposing potential of lasmiditan for the treatment of AKI and/or KD onset/progression."

Journal • Preclinical • Acute Kidney Injury • Cardiovascular • CNS Disorders • Fibrosis • Immunology • Metabolic Disorders • Migraine • Nephrology • Pain • Renal Disease • Reperfusion Injury

The Spectrum of Headaches in Moyamoya Angiopathy: From Mechanisms to Management Strategies-A Consensus Review From the NEUROVASC Working Group. (PubMed, Eur J Neurol) - "Headache is a frequent and clinically relevant manifestation of MMA that significantly impacts quality of life. Evidence on optimal management remains scarce, and current strategies are largely empirical. Further studies are needed to clarify pathogenic mechanisms, refine patient selection for surgical interventions, and evaluate pharmacological treatments, including novel agents, to improve clinical outcomes."

Journal • Review • Cardiovascular • CNS Disorders • Migraine • Pain • Vascular Neurology

Lasmiditan in Migraine Management: An Advanced Review of Its Pharmacological Paradigm, Clinical Applications, Safety Considerations, Drug Interaction Spectrum, and Regulatory Approval. (PubMed, Drug Res (Stuttg)) - "Cell studies reveal its receptor activity and transport mechanisms, enhancing therapeutic understanding.Lasmiditan represents a groundbreaking addition to migraine therapeutics, providing a targeted, non-vasoconstrictive alternative. Its safety, tolerability, and efficacy make it a strong alternative for patients unsuitable for traditional treatments, with ongoing research likely to expand its clinical relevance."

Journal • CNS Disorders • Migraine • Pain

SEROTONIN MODULATION IN MIGRAINE: FROM PATHOPHYSIOLOGY TO TREATMENT (IHC 2025) - "Lasmiditan, a selective 5-HT1F receptor agonist, showed superior efficacy to placebo in reducing pain up to two hours after administration (OR: 2.02), in all the doses tested (50, 100 and 200 mg), with better results in the 100 and 200 mg doses, as well as less need for rescue medication...The presence of dizziness as an adverse effect, which is also common in migraine attacks, is not a significant limitation to its use. The findings support the continuation of research with other molecules in the class, with the aim of expanding therapeutic options and optimizing the individualization of treatment."

CNS Disorders • Migraine

Real-World Patterns of Acute Medication Use Among Migraine Patients: Insights from the I-GRAINE Registry (IHC 2025) - "Nonetheless, a substantial proportion of patients reported only partial response or adverse events, highlighting the need for individualized therapy and consideration of newer acute treatments like gepants and lasmiditan. Registry-based data such as I-GRAINE can support optimization of real-world treatment strategies in migraine care."

Clinical • Real-world • Real-world evidence • CNS Disorders • Migraine

The efficacy of various acute medicine for osmophobia, and characteristics in Japanese migraineurs. (IHC 2025) - "Triptans are effective compared to lasmiditan and NSAIDs as acute medicine. Conclusion The reasons sumatriptan and naratriptan are more effective might be because the effect is fast (sumatriptan includes nasal spray and subcutaneous injection), and the effect of naratriptan is long-acting. It remains to be seen how preventive medications including anti-CGRP monoclonal antibodies affect odor triggers and osmophobia."

Clinical • CNS Disorders • Migraine

Title: Effectiveness and tolerability of lasmiDitAn as acute migRaine Treatment (DART): a real-world multicentric study (IHC 2025) - P | "While adverse events were frequent, they were generally mild and self-limiting. These findings support lasmiditan as a viable option for acute migraine treatment."

Clinical • Real-world • Real-world evidence • CNS Disorders • Migraine

Investigation of the Relationship Between Weather and Headache Attacks Among Patients Using Smartphone Application Analyzed with Artificial Intelligence (IHC 2025) - "Methods From a database of 2 million users (Jan–Dec 2023), we identified individuals with episodic migraine who used triptan or lasmiditan and had 1–14 monthly headache days...BP, barometric pressure, PCA, principal component analysis. Conclusion Using real-world big data, we demonstrated that multiple weather variables—including increased rainfall, longer sunlight, stronger wind, and decreased barometric pressure changes—are associated with hourly headache occurrence."

Clinical • CNS Disorders • Migraine

Non-headache symptoms in migraine across different phases and their associations with disease characteristics and treatment outcome. (IHC 2025) - "The effect of standard established abortive drugs (triptans, Lasmiditan and NSAIDs) on MBS during headache phase was captured using a simple scale (0: not relieved, 1: partially relieved, 2: completely relived) Results A total of 126 migraine patients were enrolled (115F:11M; mean age 30.2 ± 9.5; 81EM,45 CM)...Higher number of NHS during headache phase resulted in worse disability. Standard oral acute treatments were effective in relieving MBS in a large proportion of patients."

Clinical • CNS Disorders • Migraine

Comparative Efficacy of Over-the-Counter versus Oral Prescription Medications for Acute Treatment of Episodic Migraine – A Meta-Analysis (PAINWeek 2025) - "Background: Oral over-the-counter (OTC) analgesics such as acetaminophen-aspirin-caffeine (AAC) and ibuprofen (IBU) are widely used as first-line treatments for episodic migraine. Recently approved oral prescription (Rx) agents including gepants (ubrogepant [UBR], rimegepant [RIM]) and a selective 5-HT 1F agonist lasmiditan (LAS), offer alternative options... Thirty two studies evaluating OTC and Rx oral treatments for episodic migraine were included in the meta-analysis. All active treatments were superior to placebo across pain and associated symptom endpoints. For two-hour pain relief, the highest efficacy was observed with ibuprofen 400–600 mg (RR: up to 2.21) and AAC (RR: 1.77)."

Retrospective data • CNS Disorders • Migraine • Pain

Integrative snRNA-seq, molecular docking and dynamics simulations identifies Lasmiditan as drug candidate for Alzheimer's disease. (PubMed, Clin Transl Med) - "20 key transcriptional regulators (DERs) were identified linked to AD in myeloid, and neuronal cell populations. The DERs correlated with Braak stage, APOE genotype, and aging. ETV6 is a potentially viable therapeutic target due to its ability to form stable and strongly interacting complexes across multiple drugs. Lasmiditan showed the strongest binding to ETV6 (RMSD: 2.98 Å, H-bonds: 68.38) and optimal blood-brain-barrier (BBB) penetration (LogP 3-4, TPSA 60-75). Lasmiditan is a potentially promising AD therapeutic candidate that warrants further preclinical validation."

Journal • Alzheimer's Disease • CNS Disorders • APOE • ETV6 • PAX6 • ZEB2

Real-World Experience of Lasmiditan for the Acute Treatment of Migraine. (PubMed, J Clin Neurol) - "This was the first real-world study of lasmiditan in Korean patients with migraine. Although administered at a low dosage, lasmiditan was effective in approximately half of the patients. Dizziness was the most common adverse event, and it occurred at a higher rate than in clinical trials."

Journal • Real-world evidence • CNS Disorders • Migraine • Pain

Evaluation of unmet needs and quality-of-care indicators among patients with migraine in the United States: 2021–2022 (AHS 2025) - "Following migraine QOC indicators selected based on current literature were assessed among diagnosed migraine patients: (1) migraine-related healthcare visits: emergency department (ED), urgent care, neurology, primary care, outpatient, inpatient hospitalizations in each full calendar year, and 30-day hospital readmission following the first hospitalization; (2) medication use: acute (generic [triptans, opioids, NSAIDs, ergotamines, barbiturates, and acetaminophen] and branded [Ubrogepant, Zavegepant, Lasmiditan, Rimegepant (when the first prescription is for less or equal to 8 pills)]) and preventive (oral migraine preventive medications[OMPM; anticonvulsants, antidepressants, antihypertensives, and other oral combination medications] and branded [CGRP mAbs, Botox, Atogepant, Rimegepant (when the first prescription is for >8 pills)]) migraine treatments; (3) other migraine-related diagnoses: acute medication overuse (AMO) based on medication utilization algorithm and..."

Clinical • CNS Disorders • Migraine • Pain

A retrospective cohort study comparing persistence between rimegepant and lasmiditan for the acute treatment of migraine in the US (AHS 2025) - "The rimegepant cohort was associated with a greater proportion of persistent patients compared to the lasmiditan cohort. This was seen regardless of lasmiditan index dose, chronic migraine diagnosis or prior repeated use of controlled substances. Results were robust to assumptions underlying the definition of persistence."

Retrospective data • CNS Disorders • Depression • Migraine • Pain • Psychiatry • Vascular Neurology

Real-world prescribing patterns in patients newly diagnosed with migraine in the United States from 2018 to 2021 (AHS 2025) - "Study outcomes included population demographics and clinical characteristics, utilization of acute migraine treatments (ergots, gepants, isometheptene combinations, lasmiditan, triptans), migraine-specific preventive treatments (CGRP mAbs, gepants, onabotulinumtoxin A), and other preventive treatments (beta-blockers, angiotensin converting enzyme inhibitors [ACEis], angiotensin receptor blockers [ARBs], anticonvulsants, memantine, serotonin-norepinephrine reuptake inhibitors [SNRIs], tricyclic antidepressants [TCAs]). Despite widely available migraine treatment guidelines, nearly half of patients newly diagnosed with migraine received no acute or preventive migraine prescription medications within 3 years of diagnosis. Prescribing non migraine-specific medications is common, with newer drug classes used infrequently."

Clinical • Real-world • Real-world evidence • CNS Disorders • Migraine • Pain

The dual impact of ictal and interictal burden in migraine: an analysis from the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME) Japan second study. (PubMed, J Headache Pain) - "These results revealed that high interictal burden negatively affects multiple aspects of daily life in Japanese people with migraine independently of the impact of headaches."

Journal • Observational data • CNS Disorders • Migraine • Pain

Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice. (PubMed, Neurol Int) - " Lasmiditan is likely to be effective in males with severe migraine classification and receiving CGRP-mAb treatment. If mild somnolence is a side effect, the drug can be continued and may be effective."

Journal • Real-world evidence • CNS Disorders • Migraine • Pain

Comparative Risk of Major Adverse Cardiovascular Events among Patients who Initiate Treatment with Acute Migraine Agents (ISPOR 2025) - "Our study found that ubrogepant and rimegepant were associated with a lower risk of MACE compared to sumatriptan highlighting their potential as safer alternatives for patients with cardiovascular risk. No significant difference in MACE risk was observed between lasmiditan and sumatriptan suggesting the need for further research to better understand the cardiovascular safety profile of lasmiditan."

Adverse events • Clinical • Cardiovascular • CNS Disorders • Migraine • Myocardial Infarction • Pain

A fixed-dose combination of meloxicam and rizatriptan (Symbravo) for migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain